摘要
目的:探讨小儿定喘口服液联合重组人干扰素α1b治疗儿童毛细支气管炎的临床疗效。方法:选取荆门市第一人民医院于2016年3月至2019年3月收治的儿童毛细支气管炎患者198例,按照随机数字表法将患儿分为对照组和研究组,每组99例。对照组患儿给予重组人干扰素α1b治疗,研究组患儿在对照组的基础上联合小儿定喘口服液治疗。比较两组患儿临床疗效、免疫功能指标、血清学指标水平和临床症状消失或缓解时间的差异,记录两组患儿不良反应发生情况。结果:治疗7 d后,研究组患儿的总有效率为81.82%(81/99),明显高于对照组的67.68%(67/99),差异有统计学意义(P<0.05)。治疗7 d后,两组患儿免疫球蛋白G、免疫球蛋白A及免疫球蛋白M水平均较治疗前明显升高,且研究组患儿明显高于对照组,差异均有统计学意义(P<0.05)。研究组患儿咳嗽消失时间、啰音消失时间、喘息缓解时间和发热消退时间明显短于对照组,差异均有统计学意义(P<0.05)。治疗7 d后,两组患儿降钙素原、单核细胞趋化蛋白1及白细胞介素6水平与治疗前相比明显降低,且研究组患儿明显低于对照组;两组患儿γ干扰素水平较治疗前明显升高,且研究组患儿明显高于对照组,差异均有统计学意义(P<0.05)。研究组、对照组患儿不良反应发生率分别为22.22%(22/99)、19.19%(19/99),差异无统计学意义(P>0.05)。结论:小儿定喘口服液联合重组人干扰素α1b治疗儿童毛细支气管炎的疗效确切,可迅速改善患儿临床症状,有效改善患儿机体免疫功能、血清学指标水平,安全性较好。
OBJECTIVE:To probe into the clinical efficacy of Xiaoer Dingchuan oral liquid combined with recombinant human interferonα1b in the treatment of bronchiolitis in children.METHODS:198 children with bronchiolitis admitted into the First People’s Hospital of Jingmen from Mar.2016 to Mar.2019 were selected and divided into control group and research group via random number table,with 99 cases in each group.The control group was treated with recombinant human interferonα1b,while the research group was given Xiaoer Dingchuan oral liquid based on the control group.Differences in clinical efficacy,immunologic function indicators,serological indicator,disappearance time or remission time of clinical symptoms were compared between two groups,incidences of adverse drug reactions of two groups were recorded.RESULTS:After 7-day treatment,the total effective rate of research group was 81.82%(81/99),which was significantly higher than that of the control group(67.68%,67/99),with statistically significant difference(P<0.05).After 7-day treatment,the immune globulin G,immune globulin A and immune globulin M levels of both groups had been significantly increased,and those of the research group were significantly higher than the control group,with statistically significant differences(P<0.05).The disappearance time of cough and rale,remission time of wheeze and duration of fever of research group were significantly shorter than those of the control group,with statistically significant differences(P<0.05).After 7-day treatment,the procalcitonin,monocyte chemoattractant protein-1 and interleukin-6 levels of both groups had been significantly decreased,and those of the research group were significantly lower than the control group;the interferon-γlevels of both groups had been significantly improved,and that of the research group was significantly higher than the control group,with statistically significant differences(P<0.05).The incidences of adverse drug reactions of research group and control group were respectively 22.22%(22/99)and 19.19%(19/99),the difference had no statistical significance(P>0.05).CONCLUSIONS:The efficacy of Xiaoer Dingchuan oral liquid combined with recombinant human interferonα1b in the treatment of bronchiolitis in children,which can rapidly improve clinical symptoms,effectively promote body immunity and serological indicator,with good safety.
作者
孔念华
陈爱华
张劲松
KONG Nianhua;CHEN Aihua;ZHANG Jinsong(Dept.of Pediatrics,the First People’s Hospital of Jingmen,Hubei Jingmen 448000,China;Dept.of Pediatrics,Jinjiang Traditional Chinese Medicine Hospital,Fujian Jinjiang 362200,China;Dept.of Respiratory Medicine,Jinjiang Traditional Chinese Medicine Hospital,Fujian Jinjiang 362200,China)
出处
《中国医院用药评价与分析》
2020年第6期663-666,共4页
Evaluation and Analysis of Drug-use in Hospitals of China
基金
湖北省卫生计生委科研项目(No.WJ2016MB570)。
关键词
小儿定喘口服液
重组人干扰素Α1B
儿童
支气管炎
临床研究
Xiaoer Dingchuan oral liquid
Recombinant human interferonα1b
Children
Bronchitis
Clinical study
作者简介
孔念华,副主任医师,研究方向:儿科消化及呼吸疾病,E-mail:hdhf8713@163.com。
